Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.24 and traded as low as $1.06. Akari Therapeutics shares last traded at $1.09, with a volume of 37,485 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a report on Friday. They issued a “sell” rating on the stock.
Get Our Latest Analysis on AKTX
Akari Therapeutics Stock Performance
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Akari Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Invest in the Best Canadian Stocks
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
